At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMMX Immix Biopharma, Inc.
Trading 06-09 13:15:21 EDT
7.88
+0.01
+0.13%
High8.23Low7.80Vol579.15K
Open8.01D1 Closing7.87Amplitude5.46%
Mkt Cap560.98MTradable Cap447.44MTotal Shares71.19M
T/O4.58MT/O Rate1.02%Tradable Shares56.78M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Immix Biopharma shareholders elect directors at annual meeting
Reuters  ·  05-30
Immix Biopharma shareholders elect directors at annual meeting
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biohaven Ltd. (BHVN) and Immix Biopharma (IMMX)
TIPRANKS  ·  05-27
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biohaven Ltd. (BHVN) and Immix Biopharma (IMMX)
Immix Biopharma closes $150 million common stock offering at $8.94 per share
Reuters  ·  05-23
Immix Biopharma closes $150 million common stock offering at $8.94 per share
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
THOMSON REUTERS  ·  05-23
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
Immix Biopharma Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  05-23
Immix Biopharma Is Maintained at Buy by HC Wainwright & Co.
Immix Biopharma, Inc. : H.c. Wainwright Raises Target Price to $20 From $15
THOMSON REUTERS  ·  05-22
Immix Biopharma, Inc. : H.c. Wainwright Raises Target Price to $20 From $15
Immix Biopharma Prices $150 Million Stock Offering
MT Newswires Live  ·  05-21
Immix Biopharma Prices $150 Million Stock Offering
Immix Biopharma prices USD 150 million follow-on stock offering at USD 8.94/share
Reuters  ·  05-21
Immix Biopharma prices USD 150 million follow-on stock offering at USD 8.94/share
Immix Biopharma Inc: Pricing of Offering of 16.8 Mln Shares at Price to Public of $8.94 per Share
THOMSON REUTERS  ·  05-21
Immix Biopharma Inc: Pricing of Offering of 16.8 Mln Shares at Price to Public of $8.94 per Share
Immix Biopharma Inc - Net Proceeds to Fund Nxc-201 Development, Working Capital, and Corporate Purposes
THOMSON REUTERS  ·  05-21
Immix Biopharma Inc - Net Proceeds to Fund Nxc-201 Development, Working Capital, and Corporate Purposes
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
THOMSON REUTERS  ·  05-21
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
Immix Biopharma Inc - No Relapses Observed to-Date for Patients Who Have Reached Complete Response
THOMSON REUTERS  ·  05-21
Immix Biopharma Inc - No Relapses Observed to-Date for Patients Who Have Reached Complete Response
Immix Biopharma Inc - All Four Mrd-Negative Patients Convert to Complete Response in Nexicart-2 Trial
THOMSON REUTERS  ·  05-21
Immix Biopharma Inc - All Four Mrd-Negative Patients Convert to Complete Response in Nexicart-2 Trial
Immix Biopharma Inc - All Complete Responses Reached Within 1 Year of Follow-up Post-Dosing
THOMSON REUTERS  ·  05-21
Immix Biopharma Inc - All Complete Responses Reached Within 1 Year of Follow-up Post-Dosing
Immix Biopharma says NEXICART-2 trial posts 95% complete response rate in AL amyloidosis
Reuters  ·  05-21
Immix Biopharma says NEXICART-2 trial posts 95% complete response rate in AL amyloidosis
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From Relapsed/Refractory Al Amyloidosis Clinical Trial Nexicart-2
THOMSON REUTERS  ·  05-21
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From Relapsed/Refractory Al Amyloidosis Clinical Trial Nexicart-2
Immix Biopharma, Inc: Next Nexicart-2 Update Expected Late September, 2026
THOMSON REUTERS  ·  05-21
Immix Biopharma, Inc: Next Nexicart-2 Update Expected Late September, 2026
Immix Biopharma Inc - Plans to Initiate Phase 3 Trial in Newly Diagnosed Al Amyloidosis Patients
THOMSON REUTERS  ·  05-21
Immix Biopharma Inc - Plans to Initiate Phase 3 Trial in Newly Diagnosed Al Amyloidosis Patients
Immix Biopharma: by March End 2027, Expect to Present 1-Year Follow-up Data of Enrolled Patients; Sees It to Drive Bla Submission, Commercial Launch
THOMSON REUTERS  ·  05-21
Immix Biopharma: by March End 2027, Expect to Present 1-Year Follow-up Data of Enrolled Patients; Sees It to Drive Bla Submission, Commercial Launch
Immix Biopharma posts corporate presentation on NXC-201 CAR-T for relapsed AL amyloidosis
Reuters  ·  05-15
Immix Biopharma posts corporate presentation on NXC-201 CAR-T for relapsed AL amyloidosis

Introduction

Company Name.
Immix Biopharma, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Issue price:
--